Anna Isotta Castrini

Anna Isotta Castrini

Auto-generated profile, based on publicly available information

Anna Isotta Castrini

ProCardio Center for Innovation, Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MSMarit Kristine Smedsrud
Marit Kristine Smedsrud
MCMonica Chivulescu
Monica Chivulescu
MFMarianne Inngjerdingen Forså
Marianne Inngjerdingen Forså
ICIsotta Castrini
Isotta Castrini
EAEivind Westrum Aabel
Eivind Westrum Aabel
Kristina Hermann HaugaaKristina Hermann Haugaa
Kristina Hermann Haugaa
This study aimed to explore the incidence of severe cardiac events in paediatric arrhythmogenic right ventricular cardiomyopathy (ARVC) patients and ARVC penetrance in paediatric relatives. Furthermore, the phenotype in childhood-onset ARVC was described. Consecutive ARVC paediatric patients and genotype positive relatives ≤18 years of age were followed with electrocardiographic, structural, and arrhythmic characteristics according to the 2010 revised Task Force Criteria. Penetrance of ARVC disease was defined as fulfilling definite ARVC criteria and severe cardiac events were defined as cardiac death, heart transplantation (HTx) or severe ventricular arrhythmias. Childhood-onset disease was defined as meeting definite ARVC criteria ≤12 years of age. Among 62 individuals [age 9.8 (5.0–14.0) years, 11 probands], 20 (32%) fulfilled definite ARVC diagnosis, of which 8 (40%) had childhood-onset disease. The incidence of severe cardiac events was 23% (n = 14) by last follow-up and half of them occurred in patients ≤12 years of age. Among the eight patients with childhood-onset disease, five had biventricular involvement needing HTx and three had severe arrhythmic events. Among the 51 relatives, 6% (n = 3) met definite ARVC criteria at time of genetic diagnosis, increasing to 18% (n = 9) at end of follow-up. In a paediatric ARVC cohort, there was a high incidence of severe cardiac events and half of them occurred in children ≤12 years of age. The ARVC penetrance in genotype positive paediatric relatives was 18%. These findings of a high-malignant phenotype in childhood-onset ARVC indicate a need for ARVC family screening at younger age than currently recommended. Highly malignant disease in childhood-onset arrhythmogenic right ventricular cardiomyopathy: study design and summary results. In a paediatric ARVC cohort, childhood-onset ARVC was found in 40% of all patients with a definite diagnosis. There was a 23% cumulative incidence of severecardiac events and half of them occurred in children ≤12 years of age. The ARVC penetrance in genotype positive paediatric relatives was 18%.

5 October 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
CFChristian Five
Christian Five
NHNina E Hasselberg
Nina E Hasselberg
LALinda T Aaserud
Linda T Aaserud
ACAnna Isotta Castrini
Anna Isotta Castrini
KVKatarina Vlaisavljevic
Katarina Vlaisavljevic
Kristina Hermann HaugaaKristina Hermann Haugaa
Kristina Hermann Haugaa
Patients with mitral valve prolapse (MVP) have high risk of life-threatening ventricular arrhythmias (VAs). Data on the impact of exercise on arrhythmic risk in these patients are lacking. We explored whether lifetime exercise dose was associated with severe VA and with established risk factors in patients with MVP. Furthermore, we explored the circumstances at the VA event. In this retrospective cohort study, we included patients with MVP and assessed lifetime exercise dose as metabolic equivalents of task (MET) hours/week. Severe VA was defined as sustained ventricular tachycardia or fibrillation, aborted cardiac arrest, and appropriate shock by a primary preventive implantable cardioverter defibrillator. We included 136 MVP patients (48 years [interquartile range (IQR) 35–59], 61% female), and 17 (13%) had previous severe VA. The lifetime exercise dose did not differ in patients with and without severe VA (17 MET h/week [IQR 9–27] vs. 14 MET h/week [IQR 6–31], P = 0.34). Lifetime exercise dose > 9.6 MET h/week was a borderline significant marker for severe VA (OR 3.38, 95% CI 0.92–12.40, P = 0.07), while not when adjusted for age (OR 2.63, 95% CI 0.66–10.56, P = 0.17). Ventricular arrhythmia events occurred most frequently during wakeful rest (53%), followed by exercise (29%) and sleep (12%). We found no clear association between moderate lifetime exercise dose and severe VA in patients with MVP. We cannot exclude an upper threshold for safe levels of exercise. Further studies are needed to explore exercise and risk of severe VA.

19 April 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
ACAnna I. Castrini
Anna I. Castrini
ESEystein Skjølsvik
Eystein Skjølsvik
MEMette E. Estensen
Mette E. Estensen
VAVibeke Marie Almaas
Vibeke Marie Almaas
HSHelge Skulstad
Helge Skulstad
Kristina Hermann HaugaaKristina Hermann Haugaa
Kristina Hermann Haugaa
Background: We aimed to assess the association between number of pregnancies and long‐term progression of cardiac dysfunction, arrhythmias, and event‐free survival in women with pathogenic or likely pathogenic variants of gene encoding for Lamin A/C proteins ( LMNA+). Methods and Results: We retrospectively included consecutive women with LMNA+ and recorded pregnancy data. We collected echocardiographic data, occurrence of atrial fibrillation, atrioventricular block, sustained ventricular arrhythmias, and implantation of cardiac electronic devices (implantable cardioverter defibrillator/cardiac resynchronization therapy defibrillator). We analyzed retrospectively complications during pregnancy and the peripartum period. We included 89 women with LMNA+ (28% probands, age 41±16 years), of which 60 had experienced pregnancy. Follow‐up time was 5 [interquartile range, 3–9] years. We analyzed 452 repeated echocardiographic examinations. Number of pregnancies was not associated with increased long‐term risk of atrial fibrillation, atrioventricular block, sustained ventricular arrhythmias, or implantable cardioverter defibrillator/cardiac resynchronization therapy defibrillator implantation. Women with previous pregnancy and nulliparous women had a similar annual deterioration of left ventricular ejection fraction (−0.5/year versus −0.3/year, P =0.37) and similar increase of left ventricular end‐diastolic diameter (0.1/year versus 0.2/year, P =0.09). Number of pregnancies did not decrease survival free from death, left ventricular assist device, or need for cardiac transplantation. Arrhythmias occurred during 9% of pregnancies. No increase in maternal and fetal complications was observed. Conclusions: In our cohort of women with LMNA+, pregnancy did not seem associated with long‐term adverse disease progression or event‐free survival. Likewise, women with LMNA+ generally well‐tolerated pregnancy, with a small proportion of patients experiencing arrhythmias.

6 April 2021 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
ESEystein T Skjølsvik
Eystein T Skjølsvik
ØLØyvind Haugen Lie
Øyvind Haugen Lie
MCMonica Chivulescu
Monica Chivulescu
MRMargareth Ribe
Margareth Ribe
ACAnna Isotta Castrini
Anna Isotta Castrini
Kristina Hermann HaugaaKristina Hermann Haugaa
Kristina Hermann Haugaa
Aims: We aimed to study the progression of cardiac dysfunction in patients with lamin A/C mutations and explore markers of adverse cardiac outcome. Methods and results: We followed consecutive lamin A/C genotype-positive patients divided into tertiles according to age. Patients underwent repeated clinical examinations, electrocardiograms (ECGs), and echocardiograms. We followed left ventricular (LV) and right ventricular (RV) size and function, and the severity atrioventricular-valve regurgitations. Outcome was death, LVAD implant, or cardiac transplantation. We included 101 patients [age 44 (29–54) years, 39% probands, 50% female]. We analysed 576 echocardiograms and 258 ECGs during a follow-up of 4.9 (interquartile range 2.5–8.2) years. The PR-interval increased at young age from 204 ± 73 to 212 ± 69 ms (P < 0.001), LV ejection fraction (LVEF) declined from middle age from 50 ± 12% to 47 ± 13% (P < 0.001), while LV volumes remained unchanged. RV function and tricuspid regurgitation worsened from middle age with accelerating rates. Progression of RV dysfunction [odds ratio (OR) 1.3, 95% confidence interval (CI) (1.03–1.65), P = 0.03] and tricuspid regurgitation [OR 4.9, 95% CI (1.64–14.9), P = 0.004] were associated with outcome when adjusted for age, sex, comorbidities, LVEF, and New York Heart Association functional class. Conclusion: In patients with lamin A/C genotype, electrical disease started at young age. From middle age, LV function deteriorated progressively, while LV size remained unchanged. Worsening of RV function and tricuspid regurgitation accelerated in older age and were associated with outcome. Our systematic map on cardiac deterioration may help optimal monitoring and prognostication in lamin A/C disease.

15 July 2025 in JACC: Cardiovascular Imaging
Verified
Journal Article
Open access
LALinda T. Aaserud
Linda T. Aaserud
CRChristine Rootwelt-Norberg
Christine Rootwelt-Norberg
POPaul A.S. Olsen
Paul A.S. Olsen
CFChristian Five
Christian Five
ACAnna I. Castrini
Anna I. Castrini
ØLØyvind H. Lie
Øyvind H. Lie
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inheritable heart disease, whereas exercise-induced arrhythmogenic cardiomyopathy (EiAC) is a proposed acquired similar phenotype in athletes. The differences in disease progression between these entities are not well understood. This study aims to assess structural, functional, and arrhythmic disease progression in EiAC compared with ARVC. This longitudinal cohort study included EiAC patients who were competitive endurance athletes (>24 MET-hours/week for >6 consecutive years) referred due to ventricular arrhythmias (VA), without inherited or genetic factors or other evident causes, and genotype-positive ARVC patients with a definite diagnosis and their genotype-positive family members for comparison. Disease progression was assessed by repeated echocardiographic examinations and incident VA during long-term follow-up. The authors included 125 ARVC patients (61 women, aged 38 ± 17 years) and 41 EiAC patients (6 women, aged 45 ± 13 years) and followed them for 96 months (Q1-Q3: 73-132 months) and 82 months (Q1-Q3: 50-118 months), respectively. The authors analyzed 730 echocardiographic examinations (538 ARVC, 192 EiAC). Right ventricular (RV) structure and function remained stable in EiAC patients, whereas those in ARVC patients deteriorated during follow-up. The 5-year and 10-year cumulative incidences of VA were similar between EiAC and ARVC patients. RV structure and function deteriorated in ARVC patients but remained stable in EiAC patients during follow-up. The incidence of VA was high in both populations. These results indicate that EiAC patients should be followed closely over time regardless of structural and functional progression.

30 April 2025 in Computers in Biology and Medicine
Verified
Journal Article
Open access
GMGiulia Monopoli
Giulia Monopoli
DHDaniel Haas
Daniel Haas
ASAshay Singh
Ashay Singh
EAEivind Westrum Aabel
Eivind Westrum Aabel
MRMargareth Ribe
Margareth Ribe
MMMary M. Maleckar
Mary M. Maleckar
Mitral valve (MV) assessment is key to diagnosing valvular disease and to addressing its serious downstream complications. Cardiac magnetic resonance (CMR) has become an essential diagnostic tool in MV disease, offering detailed views of the valve structure and function, and overcoming the limitations of other imaging modalities. Automated detection of the MV leaflets in CMR could enable rapid and precise assessments that enhance diagnostic accuracy. To address this gap, we introduce DeepValve, the first deep learning (DL) pipeline for MV detection using CMR. Within DeepValve, we tested three valve detection models: a keypoint-regression model (UNET-REG), a segmentation model (UNET-SEG) and a hybrid model based on keypoint detection (DSNT-REG). We also propose metrics for evaluating the quality of MV detection, including Procrustes-based metrics (UNET-REG, DSNT-REG) and customized Dice-based metrics (UNET-SEG). We developed and tested our models on a clinical dataset comprising 120 CMR images from patients with confirmed MV disease (mitral valve prolapse and mitral annular disjunction). Our results show that DSNT-REG delivered the best regression performance, accurately locating landmark locations. UNET-SEG achieved satisfactory Dice and customized Dice scores, also accurately predicting valve location and topology. Overall, our work represents a critical first step towards automated MV assessment using DL in CMR and paving the way for improved clinical assessment in MV disease.